EUCTR2009-013351-30-DE进行中（未招募）1 期
A phase I/II trail to evaluate the safety, feasibility and efficacy of the addition of temsirolimus (Torisel™) to a regimen of bendamustine and rituximab for the treatment of patients with follicular lymphoma or mantle cell lymphoma in fist to third relapse - BERT
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically proven diagnosis of follicular non-Hodgkin's lymphoma grades l, II or IIIA or mantle cell lymphoma (including Cyclin D1 expression) according to the World Health Organization classification
- •Documented relapse or progression following at least one but not more than 3 antineoplastic treatments
- •At least 1 measurable tumor mass (>1.5 cm x >1.0 cm) or bone marrow infiltration
- •subjects 18 years or older
- •Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
- •Adequate bone marrow reserve: Platelets of at least 75000/µl, absolute neutrophil count at least 1500/µl. In case of extensive bone marrow infiltration and lower platelet or absolute neutrophil counts, patients can not be included in the phase I part of the trial. In the phase II proportion of the trial patients may be included with a platelet count of more or equal to 50000/µl on the discretion of the investigator, if thrombocytopenia is associated with massive bone marrow infiltration.
- •adequate hepatic and renal function
- •oAlanine aminotransferase <2.5 x upper limit of normal (ULN); Aspartate aminotransferase <2.5 x ULN, Total bilirubin <1.5 x ULN
- •oMeasured or calculated creatinine clearance >50 mL/min
- •Eastern Cooperative Oncology Group [ECOG] performance Status 0-2
- •Female subject must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and have a negative serum ß-hCG pregnancy test at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Lymphoma other than MCL or FL
- •Active central nervous System lymphoma. Brain MRI is required only if clinically indicated
- •pregnancy or breast feeding women
- •severe concomitant disease (e.g. uncontrolled arterial hypertension, heart failure (NYHA III-IV), uncontrolled diabetes mellitus, pulmonary fibrosis, uncontrolled hyperlipoproteinemia)
- •active uncontrolled infections including HIV-positivity, active Hep B or C
- •mental status precluding patient’s compliance
- •Comedication with strong CYP 3A4/5-inhibitors or –inducers (Appendix 22.7)
- •Prior treatment with Temsirolimus
- •Known CD20 negativity
- •Patients refractory to Bendamustine in a prior treatment line, defined as relapse within 1 year after initiation of first cycle. Exception: termination of treatment prior to third scheduled cycle for reasons other than toxicity.
- •Status post allogeneic transplantation
- •Peripheral neuropathy or neuropathic pain of Grade 2 or worse
- •Diagnosed or treated for a malignancy other than NHL except: adequately
- •treated non-melanoma skin cancer, curatively treated in-situ cancer of the
- •cervix, DCIS of the breast, or other solid tumors curatively treated with
- •no evidence of disease for >5 years
- •Concurrent treatment with another investigational agent. Concurrent participation in non-treatment studies is not excluded.
- •Known intolerance to sirolimus or derivates, or Bendamustine or Rituximab.
研究者
相似试验
进行中（未招募）
不适用
Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambersDetection of thrombi in the arterial vasculature and cardiac chambersEUCTR2004-004701-23-DEEpix Pharmaceuticals, Inc.32
进行中（未招募）
不适用
Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambersDetection of thrombi in the arterial vasculature and cardiac chambersEUCTR2004-004701-23-CZEpix Pharmaceuticals, Inc.32
进行中（未招募）
不适用
SHORE-studyEUCTR2010-020171-23-DE4SC AG80
进行中（未招募）
1 期
Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab treatment in patients with endometrial cancer after disease progression to a previous treatment with Platinum-based Chemotherapy. LiDer trialAdvanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based ChemotherapyMedDRA version: 21.0Level: PTClassification code: 10014736Term: Endometrial cancer recurrent Class: 100000004864CTIS2023-508583-30-00Vall D Hebron Institute Of Oncology58
招募中
2 期
Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy2024-517705-93-00Fundacion Oncosur140